NNNN · Anbio Biotechnology Class A Ordinary Shares

The company held two shareholder meetings on May 15, 2026, where all proposals were approved by overwhelming majorities. The key actions include a share capital reduction reducing par value from $0.0001 to $0.000000001, which may be a preparatory step for a future reverse stock split or to adjust the capital structure. The authorized share capital was dramatically increased to $3,000 divided into 3 trillion shares, including new Class C ordinary shares and preference shares, providing the board with significant flexibility for future financing, acquisitions, or stock-based compensation. Class B voting rights were increased from 50 to 500 votes per share, and Class B shares were made convertible into Class A shares at the holder's option, indicating a potential simplification or reorganization of the dual-class structure. The board was authorized to implement one or more share consolidations at ratios up to 10,000-for-1 within three years, likely to address Nasdaq compliance if the stock price falls below minimum bid requirements. Finally, the adoption of the second amended and restated memorandum and articles includes an exclusive forum clause for Cayman Islands courts, which may affect shareholder litigation. These corporate actions represent a comprehensive overhaul of the company's capital structure and governance documents, signaling management's intent to position the company for future strategic moves.